Evidence map›Paper›PMID 40804248›Full record

ArticleNPJ Parkinson's disease2025

Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.

Gennaro Pagano, Dylan Trundell, Tanya Simuni, Nicola Pavese, Kenneth Marek, Ronald B Postuma, Nima Shariati, Annabelle Monnet, Emma Moore, Evan W Davies and 6 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Gennaro PaganoRoche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery; and Translational Area, Roche Innovation Center Basel, Basel, Switzerland. gennaro.pagano@roche.com.ORCID http://orcid.org/0000-0002-6247-8988
Dylan TrundellRoche Products Ltd, Welwyn Garden City, UK.
Tanya SimuniDepartment of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Nicola PaveseClinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne, UK.
Kenneth MarekInstitute for Neurodegenerative Disorders, New Haven, CT, USA.
Ronald B PostumaDepartment of Neurology, McGill University, and Montreal Neurological Institute, Montreal, Canada.
Nima ShariatiF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Annabelle MonnetF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Emma MooreRoche Products Ltd, Welwyn Garden City, UK.
Evan W DaviesF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Hanno SvobodaRoche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery; and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.ORCID http://orcid.org/0009-0005-1910-586X
Nathalie ProssF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Azad BonniRoche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery; and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.
Tania NikolchevaF. Hoffmann-La Roche Ltd, Basel, Switzerland.
PASADENA Investigators
Prasinezumab Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40804248
PMCPMC12350808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.